Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) executives highlighted strong recent commercial performance for ZORYVE and outlined near-term regulatory and pipeline milestones during a presentation and fireside chat at TD Cowen's 46th Annual Healthcare Conference. Q4 performance and 2025 results Chief Executive Officer Frank Watanabe said the company delivered a “very strong” fourth quarter and full-year 2025, pointing to $127.5 million in fourth-quarter net revenue and $372 million for the year. Watanabe said the fourth-quarter result was above consensus expectations, and he also emphasized that the company “effectively” doubled prescriptions in 2025. ? Defense Stocks Are Soaring—AeroVironment's Earnings Could Close the Gap Chief Commercial Officer Todd Edwards added that fourth-quarter net revenue represented 29% quarter-over-quarter growth versus Q3, which included 19% demand growth . Edwards said all products in the portfolio grew in Q4 versus Q3. He also said the company continue
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]Yahoo! Finance
- Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic DermatitisGlobeNewswire
- Arcutis Biotherapeutics (ARQT) had its price target lowered by Mizuho from $37.00 to $35.00. They now have an "outperform" rating on the stock.MarketBeat
- Arcutis Management to Present at TD Cowen’s 46th Annual Health Care ConferenceGlobeNewswire
- Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? [Yahoo! Finance]Yahoo! Finance
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/3/26 - Form 4
- ARQT's page on the SEC website